{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:07:47Z","timestamp":1758820067654},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2004,7,22]],"date-time":"2004-07-22T00:00:00Z","timestamp":1090454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s00228-004-0788-2","type":"journal-article","created":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T19:53:11Z","timestamp":1090612391000},"page":"489-501","source":"Crossref","is-referenced-by-count":11,"title":["Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study"],"prefix":"10.1007","volume":"60","author":[{"given":"Deborah","family":"Layton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda V.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad A. W.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,7,22]]},"reference":[{"key":"CR1","first-page":"Celebrex","volume":"characteristics","author":"Anonymous","year":"2000","unstructured":"Anonymous (2000) Summary of product characteristics: Celebrex (celecoxib). Searle\/Pfizer","journal-title":"Summary of product"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","volume":"345","author":"FitzGerald","year":"2001","unstructured":"FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433?442","journal-title":"N Engl J Med"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1365-2044.2000.01271.x","volume":"55","author":"Kam","year":"2000","unstructured":"Kam PC, See AU (2000) Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55:442?449","journal-title":"Anaesthesia"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0009-9236(99)70113-X","volume":"65","author":"Ehrich","year":"1999","unstructured":"Ehrich EW, Dallob A, De L, I, Van Hecken A, Riendeau D, Yuan W et al (1999) Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65:336?347","journal-title":"Clin Pharmacol Ther"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0149-2918(01)80004-7","volume":"23","author":"Williams","year":"2001","unstructured":"Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS (2001) Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 23:213?227","journal-title":"Clin Ther"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","volume":"74","author":"Bensen","year":"1999","unstructured":"Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM et al (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74:1095?1105","journal-title":"Mayo Clin Proc"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","volume":"282","author":"Simon","year":"1999","unstructured":"Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC et al (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282:1921?1928","journal-title":"JAMA"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","volume":"354","author":"Emery","year":"1999","unstructured":"Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354:2106?2011","journal-title":"Lancet"},{"key":"CR9","doi-asserted-by":"crossref","unstructured":"Shakir SA (2002) PEM in the UK. In: Mann RD, Andrews E (eds) Pharmacovigilance, 1st edn. John Wiley and Sons Ltd., Chichester, pp\u00a0333?344","DOI":"10.1002\/0470853093.ch26"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2125.1998.00774.x","volume":"46","author":"Mann","year":"1998","unstructured":"Mann RD (1998) Prescription-event monitoring?recent progress and future horizons. Br J Clin Pharmacol 46:195?201","journal-title":"Br J Clin Pharmacol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1163\/157180994X00268","volume":"1","author":"Legemaate","year":"1994","unstructured":"Legemaate J (1994) The CIOMS guidelines for biomedical research involving human subjects. Eur J Health Law 1:161?165","journal-title":"Eur J Health Law"},{"key":"CR12","unstructured":"Royal College of Physicians of London (1996) Guidelines on the practice of ethical committees in medical research involving human subjects. Royal College of Physicians of London, London"},{"key":"CR13","unstructured":"Anonymous (2000) Multi-centre research ethics committees guidance notes. Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. Web address:http:\/\/www.corec.org.uk\/wordDocs\/Guidenotes.doc. Report no. appendix C"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1365-2125.2003.01763.x","volume":"55","author":"Layton","year":"2002","unstructured":"Layton D, Riley J, Wilton LW, Shakir S (2002) Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 55:166?174","journal-title":"Br J Clin Pharmacol"},{"key":"CR15","unstructured":"Shakir SAW (2004) Causality and correlation in pharmacovigilance. In: Talbot J, Waller PC (eds) Stephens? detection of new adverse drug reactions, 5th edn. John Wiley and Sons Ltd., Chichester, pp\u00a0329?343"},{"key":"CR16","first-page":"1","volume":"6","author":"Stephens","year":"1987","unstructured":"Stephens MD (1987) The diagnosis of adverse medical events associated with drug treatment. Adverse Drug React Acute Poisoning Rev 6:1?35","journal-title":"Adverse Drug React Acute Poisoning Rev"},{"key":"CR17","unstructured":"Campbell M, Daly L, Machin D (2000) Special topics. In: Altman D, Machin D, Bryant T, Gardner MJ (eds) Statistics with confidence, 2nd edn. BMJ Books, Bristol"},{"key":"CR18","unstructured":"Strom B (1994) Sample size considerations for pharmacoepidemiology studies. In: Strom B (ed) Pharmacoepidemiology, 2nd edn. John Wiley and Sons, Chichester"},{"key":"CR19","unstructured":"Machin D, Campbell M, Fayers P et al (1997) Sample size tables for clinical studies. Table 7.1. Blackwell Science Ltd., Oxford"},{"key":"CR20","unstructured":"Machin D, Campbell M, Fayers P et al (1997) Sample size tables for clinical studies. Table\u00a07.2. Blackwell Science Ltd., Oxford"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","volume":"21","author":"Malmstrom","year":"1999","unstructured":"Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ (1999) Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 21:1653?1663","journal-title":"Clin Ther"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"Heeley","year":"2001","unstructured":"Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358:1872?1873","journal-title":"Lancet"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","volume":"16","author":"Meyboom","year":"1997","unstructured":"Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW (1997) Principles of signal detection in pharmacovigilance. Drug Saf 16:355?365","journal-title":"Drug Saf"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bmj.313.7059.732","volume":"313","author":"McAvoy","year":"1996","unstructured":"McAvoy BR, Kaner EF (1996) General practice postal surveys: a questionnaire too far? BMJ 313:732?733","journal-title":"BMJ"},{"key":"CR25","first-page":"91","volume":"47","author":"Templeton","year":"1997","unstructured":"Templeton L, Deehan A, Taylor C, Drummond C, Strang J (1997) Surveying general practitioners: does a low response rate matter? Br J Gen Pract 47:91?94","journal-title":"Br J Gen Pract"},{"key":"CR26","first-page":"87","volume":"47","author":"Deehan","year":"1997","unstructured":"Deehan A, Templeton L, Taylor C, Drummond C, Strang J (1997) The effect of cash and other financial inducements on the response rate of general practitioners in a national postal study. Br J Gen Pract 47:87?90","journal-title":"Br J Gen Pract"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/pds.690","volume":"11","author":"Key","year":"2002","unstructured":"Key C, Layton D, Shakir SA (2002) Results of a postal survey of the reasons for non-response by doctors in a prescription event monitoring study of drug safety. Pharmacoepidemiol Drug Saf 11:143?148","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0895-4356(99)00024-4","volume":"52","author":"Wensing","year":"1999","unstructured":"Wensing M, Mainz J, Kramme O, Jung HP, Ribacke M (1999) Effect of mailed reminders on the response rate in surveys among patients in general practice. J Clin Epidemiol 52:585?587","journal-title":"J Clin Epidemiol"},{"key":"CR29","unstructured":"Stephens MD (2004) Introduction. In: Stephens MD (ed) Stephens? detection of new adverse drug reactions, 5th edn. John Wiley and Sons Ltd., Chichester, pp\u00a01?90"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/art.1780401104","volume":"40","author":"Simon","year":"1997","unstructured":"Simon LS, Strand V (1997) Clinical response to nonsteroidal antiinflammatory drugs. Arthritis Rheum 40:1940?1943","journal-title":"Arthritis Rheum"},{"key":"CR31","doi-asserted-by":"crossref","unstructured":"Tive L (2000) Celecoxib clinical profile. Rheumatology (Oxford) 39[Suppl 2]:21?28","DOI":"10.1093\/rheumatology\/39.suppl_2.21"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284:1247?1255","journal-title":"JAMA"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/S0002-9343(99)00366-6","volume":"107","author":"McCarthy","year":"1999","unstructured":"McCarthy DM (1999) Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 107:37S?46S","journal-title":"Am J Med"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.324.7349.1287","volume":"324","author":"Juni","year":"2002","unstructured":"Juni P, Rutjes AW, Dieppe PA (2002) Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324:1287?1288","journal-title":"BMJ"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bmj.325.7356.161","volume":"325","author":"Geis","year":"2002","unstructured":"Geis GS (2002) Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia?s response to editorial. BMJ 325:161","journal-title":"BMJ"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/00365529609031975","volume":"31","author":"Hansen","year":"1996","unstructured":"Hansen JM, Hallas J, Lauritsen JM, Bytzer P (1996) Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 31:126?130","journal-title":"Scand J Gastroenterol"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","volume":"340","author":"Wolfe","year":"1999","unstructured":"Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888?1899","journal-title":"N Engl J Med"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","volume":"120","author":"Laine","year":"2001","unstructured":"Laine L (2001) Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120:594?606","journal-title":"Gastroenterology"},{"key":"CR39","first-page":"15","volume":"committee","author":"Anonymous","year":"2003","unstructured":"Anonymous (2003) Serious gastrointestinal effects with celecoxib and rofecoxib. Australian adverse drug reactions advisory committee (ed) Australian Adverse Drug Reactions Bulletin 22:15","journal-title":"Australian adverse drug reactions advisory"},{"key":"CR40","doi-asserted-by":"crossref","unstructured":"Garcia Rodriguez LA (1997) Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 26[Suppl 1]:16?20","DOI":"10.1016\/S0049-0172(97)80048-0"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","volume":"325","author":"Deeks","year":"2002","unstructured":"Deeks JJ, Smith LA, Bradley MD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325:619","journal-title":"BMJ"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","volume":"325","author":"Mamdani","year":"2002","unstructured":"Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G et al (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325:624","journal-title":"BMJ"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2125.2000.00229.x","volume":"50","author":"Martin","year":"2000","unstructured":"Martin RM, Biswas P, Mann RD (2000) The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 50:35?42","journal-title":"Br J Clin Pharmacol"},{"key":"CR44","first-page":"1015","volume":"29","author":"Wolfe","year":"2002","unstructured":"Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D (2002) Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 29:1015?1022","journal-title":"J Rheumatol"},{"key":"CR45","doi-asserted-by":"crossref","unstructured":"Layton D, Hughes K, Harris S, Shakir SA (2003) Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 42:1332?1341","DOI":"10.1093\/rheumatology\/keg376"},{"key":"CR46","doi-asserted-by":"crossref","unstructured":"Layton D, Heeley E, Hughes K, Shakir SA (2003) Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (Oxford) 42:622?631","DOI":"10.1093\/rheumatology\/keg141"},{"key":"CR47","doi-asserted-by":"crossref","unstructured":"Layton D, Hughes K, Harris S, Shakir SA (2003) Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 42:1354?1365","DOI":"10.1093\/rheumatology\/keg401"},{"key":"CR48","doi-asserted-by":"crossref","unstructured":"Layton D, Heeley E, Hughes K, Shakir SA (2003) Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 42:1342?1353","DOI":"10.1093\/rheumatology\/keg379"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/0003-4819-107-4-513","volume":"107","author":"Kaufmann","year":"1987","unstructured":"Kaufmann HJ, Taubin HL (1987) Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 107:513?516","journal-title":"Ann Intern Med"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archinte.160.7.913","volume":"160","author":"Lipsky","year":"2000","unstructured":"Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS et al (2000) Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 160:913?920","journal-title":"Arch Intern Med"},{"key":"CR51","first-page":"1338","volume":"27","author":"Lipsky","year":"2000","unstructured":"Lipsky PE, Abramson SB, Breedveld FC, Brook P, Burmester R, Buttgereit F et al (2000) Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 27:1338?1340","journal-title":"J Rheumatol"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0002-9343(99)00363-0","volume":"107","author":"Wallace","year":"1999","unstructured":"Wallace JL (1999) Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti- inflammatory drugs (NSAIDs). Am J Med 107:11S?16S","journal-title":"Am J Med"},{"key":"CR53","unstructured":"Anonymouse (2001) Food and Drug Administration advisory committee. Cardiovascular safety review of rofecoxib.http:\/\/www fda gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b2_06_cardio pdf 2001. Cited 8 September 2001"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"78S","DOI":"10.1016\/S0002-9343(99)00371-X","volume":"107","author":"Freston","year":"1999","unstructured":"Freston JW (1999) Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med 107:78S?88S","journal-title":"Am J Med"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R","volume":"43","author":"Crofford","year":"2000","unstructured":"Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F et al (2000) Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum 43:1891?1896","journal-title":"Arthritis Rheum"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5694\/j.1326-5377.2001.tb143099.x","volume":"175","author":"Cleland","year":"2001","unstructured":"Cleland LG, James MJ, Stamp LK, Penglis PS (2001) COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 175:214?2147","journal-title":"Med J Aust"},{"key":"CR57","doi-asserted-by":"crossref","unstructured":"Clark DW, Layton D, Shakir SAW (2004) Do some inhibitors of cyclooxygenase-2 (COX-2) increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf (in press)","DOI":"10.2165\/00002018-200427070-00002"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/00912700022008766","volume":"40","author":"Leese","year":"2000","unstructured":"Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40:124?132","journal-title":"J Clin Pharmacol"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","volume":"89","author":"White","year":"2002","unstructured":"White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM et al (2002) Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89:425?430","journal-title":"Am J Cardiol"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","volume":"92","author":"White","year":"2003","unstructured":"White WB, Faich G, Borer JS, Makuch RW (2003) Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 92:411?418","journal-title":"Am J Cardiol"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","volume":"360","author":"Ray","year":"2002","unstructured":"Ray W, Stein C, Daugherty J, Hall K, Arbogast P, Griffin M (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360:1071","journal-title":"Lancet"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archinte.163.4.481","volume":"163","author":"Mamdani","year":"2003","unstructured":"Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G et al (2003) Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 163:481?486","journal-title":"Arch Intern Med"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809?1817","journal-title":"N Engl J Med"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","volume":"8","author":"Whelton","year":"2001","unstructured":"Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM (2001) Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8:85?95","journal-title":"Am J Ther"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","volume":"7","author":"Whelton","year":"2000","unstructured":"Whelton A, Maurath CJ, Verburg KM, Geis GS (2000) Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7:159?175","journal-title":"Am J Ther"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1345\/aph.1A030","volume":"36","author":"Alkhuja","year":"2002","unstructured":"Alkhuja S, Menkel RA, Alwarshetty M, Ibrahimbacha AM (2002) Celecoxib-induced nonoliguric acute renal failure. Ann Pharmacother 36:52?54","journal-title":"Ann Pharmacother"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V","volume":"43","author":"Crofford","year":"2000","unstructured":"Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB (2000) Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 43:4?13","journal-title":"Arthritis Rheum"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJM200112203452518","volume":"345","author":"Schellenberg","year":"2001","unstructured":"Schellenberg RR, Isserow SH (2001) Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 345:1856","journal-title":"N Engl J Med"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM200101113440215","volume":"344","author":"Dahlen","year":"2001","unstructured":"Dahlen B, Szczeklik A, Murray JJ (2001) Celecoxib in patients with asthma and aspirin intolerance. The celecoxib in aspirin-intolerant asthma study group. N Engl J Med 344:142","journal-title":"N Engl J Med"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1067\/mai.2003.1450","volume":"111","author":"Gyllfors","year":"2003","unstructured":"Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J et al (2003) Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 111:1116?1121","journal-title":"J Allergy Clin Immunol"},{"key":"CR71","first-page":"167","volume":"9","author":"Tredger","year":"2002","unstructured":"Tredger JM, Stoll S (2002) Cytochromes P450?their impact on drug treatment. Hospital Pharmacist 9:167?173","journal-title":"Hospital Pharmacist"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bmj.323.7303.23","volume":"323","author":"O","year":"2001","unstructured":"O?Beirne JP, Cairns SR (2001) Drug points: cholestatic hepatitis in association with celecoxib. BMJ 323:23","journal-title":"BMJ"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7326\/0003-4819-137-1-200207020-00030","volume":"137","author":"Alegria","year":"2002","unstructured":"Alegria P, Lebre L, Chagas C (2002) Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med 137:75","journal-title":"Ann Intern Med"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.160.4.553","volume":"160","author":"Carrillo-Jimenez","year":"2000","unstructured":"Carrillo-Jimenez R, Nurnberger M (2000) Celecoxib-induced acute pancreatitis and hepatitis: a case report. Arch Intern Med 160:553?554","journal-title":"Arch Intern Med"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.305.6858.865","volume":"305","author":"Garcia","year":"1992","unstructured":"Garcia Rodriguez LA, Perez GS, Walker AM, Lueck L (1992) The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 305:865?868","journal-title":"BMJ"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/bmj.324.7340.789\/a","volume":"324","author":"Arellano","year":"2002","unstructured":"Arellano FM, Zhao SZ, Reynolds MW (2002) Case of cholestatic hepatitis with celecoxib did not fulfil international criteria. BMJ 324:789","journal-title":"BMJ"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002018-200124040-00001","volume":"24","author":"Knowles","year":"2001","unstructured":"Knowles S, Shapiro L, Shear NH (2001) Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of ?sulfa? allergy. Drug Saf 24:239?247","journal-title":"Drug Saf"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1185\/0300799039117065","volume":"17","author":"Wiholm","year":"2001","unstructured":"Wiholm BE (2001) Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. Curr Med Res Opin 17:210?216","journal-title":"Curr Med Res Opin"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJM199906243402516","volume":"340","author":"Mohammed","year":"1999","unstructured":"Mohammed S, Croom DW (1999) Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor. N Engl J Med 340:2005?2006","journal-title":"N Engl J Med"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(02)07922-9","volume":"359","author":"Schneider","year":"2002","unstructured":"Schneider F, Meziani F, Chartier C, Alt M, Jaeger A (2002) Fatal allergic vasculitis associated with celecoxib. Lancet 359:852?853","journal-title":"Lancet"},{"key":"CR81","first-page":"2553","volume":"28","author":"Kelkar","year":"2001","unstructured":"Kelkar PS, Butterfield JH, Teaford HG (2001) Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 28:2553?2554","journal-title":"J Rheumatol"},{"key":"CR82","first-page":"146","volume":"54","author":"Gill","year":"2001","unstructured":"Gill S, Hermolin R (2001) Case report of a Stevens-Johnson type reaction to celecoxib. Can J Hosp Pharm 54:146","journal-title":"Can J Hosp Pharm"},{"key":"CR83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1034\/j.1398-9995.2002.1n3581.x","volume":"57","author":"Grob","year":"2002","unstructured":"Grob M, Pichler WJ, Wuthrich B (2002) Anaphylaxis to celecoxib. Allergy 57:264?265","journal-title":"Allergy"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1592\/phco.22.8.637.33200","volume":"22","author":"Ernst","year":"2002","unstructured":"Ernst EJ, Egge JA (2002) Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy 22:637?640","journal-title":"Pharmacotherapy"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/thorax.57.5.465","volume":"57","author":"Mehandru","year":"2002","unstructured":"Mehandru S, Smith RL, Sidhu GS, Cassai N, Aranda CP (2002) Migratory pulmonary infiltrates in a patient with rheumatoid arthritis. Thorax 57:465?467","journal-title":"Thorax"},{"key":"CR86","unstructured":"CARM (2002) Acute psychiatric events with COX-2 inhibitors"},{"key":"CR87","first-page":"3","volume":"commitee","author":"Anonymous","year":"2003","unstructured":"Anonymous (2003) Acute neuropsychiatric events with celecoxib and rofecoxib. Australian adverse drug reactions advisory commitee (ed) Australian Adverse Drug Reactions Bulletin 22:3","journal-title":"Australian adverse drug reactions advisory"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1592\/phco.21.1.114.34445","volume":"21","author":"Lund","year":"2001","unstructured":"Lund BC, Neiman RF (2001) Visual disturbance associated with celecoxib. Pharmacotherapy 21:114?115","journal-title":"Pharmacotherapy"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/bmj.327.7425.1214","volume":"327","author":"Coulter","year":"2003","unstructured":"Coulter DM, Clark DW, Savage RL (2003) Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 327:1214?1215","journal-title":"BMJ"},{"key":"CR90","unstructured":"Anonymous (2003) Meeting of the committee for proprietary medicinal products (CPMP). Press release. Doc Ref: EMEA\/CPMP\/5732\/03. Web address:http:\/\/www.emea.eu.int\/htms\/hotpress\/h573203.htm. The European Agency for the Evaluation of Medicinal Products (EMEA) 21 November 2003. Cited 25 November 2003"},{"key":"CR91","unstructured":"Anonymous (2001) National institute of clinical excellence. guidance on use of cyclo-oxygenase (COX II) selective inhibitors celecoxib, rofecoxib, meloxicam and etodoloac for osteoarthritis and rheumatoid arthritis. Report No. Technology Appraisal No.27. Department of Health, London"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-004-0788-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-004-0788-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-004-0788-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T21:06:16Z","timestamp":1585861576000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-004-0788-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,22]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s00228-004-0788-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,22]]}}}